MAQS advises Ribocure in connection with a USD 33 million capital raising

Swedish investors Erik Selin and Jacob Torell have joined Ribocure Pharmaceuticals as new shareholders through an investment corresponding to USD 33 million in total. Following the investment Erik Selin holds 32.65% of the shares in Ribocure shares, while Jacob Torell holds 1% of the shares in Ribocure.

Ribocure Pharmaceuticals, located at GoCo Health Innovation City in Mölndal, is a pioneering Swedish biotech company dedicated to developing advanced siRNA-based therapies to address some of today’s most urgent medical challenges.

This investment marks an important milestone in Ribocure’s growth journey in Sweden and facilitates further development and advancement of the company's multi-specific siRNA platform and proprietary CNS delivery technology, paving the way for significant progress toward groundbreaking therapies for cardiovascular and neurodegenerative disorders.

MAQS Advokatbyrå has advised Ribocure Pharmaceuticals in the transaction with a team primarily consisting of Niklas Eskilsson, Marcus Resvik, Sandra Andersson and Fredrik Brusberg.